Search

Displaying results 4121 - 4130 of 8700 in total
  1. Drug

    Ubenimex

    go.drugbank.com/drugs/DB03424
    Investigational

    It is an inhibitor of aminopeptidase B, leukotriene A4 hydrolase, aminopeptidase N. It is being studied for use in the treatment of acute myelocytic leukemia.

  2. Drug

    Crofelemer

    go.drugbank.com/drugs/DB04941
    ApprovedInvestigational

    It is marketed under the brand name Fulyzaq and indicated for the symptomatic treatment of non-infectious diarrhea in adult patients with HIV/AIDS who are taking antiretroviral therapy.

  3. Drug

    Norclozapine

    go.drugbank.com/drugs/DB05766
    Investigational

    ACP-104, or N-desmethylclozapine, is the major metabolite of clozapine, and is being developed by ACADIA as a novel, stand-alone therapy for schizophrenia. … It combines an atypical antipsychotic efficacy profile with the added potential benefit of enhanced cognition, thereby addressing one of the major challenges in treating schizophrenia today.

  4. Drug

    Atractylodes japonica root oil

    go.drugbank.com/drugs/DB11270
    ApprovedWithdrawn

    It is present in some cosmetic products such as whitening creams as an active ingredient and lubricant for skin irritation.

  5. Drug

    INM005

    go.drugbank.com/drugs/DB16499
    Investigational

    INM005 was under investigation in clinical trials for the treatment of COVID-19. It was studied for pharmacokinetics, efficacy, and safety in a completed trial (NCT04494984). … Additionally, a retrospective cohort study investigated the effectiveness and safety of specific hyperimmune equine serum for severe hospitalized COVID-19 patients (NCT04954235)

    Categories: Experimental Unapproved Treatments for COVID-19
  6. Drug

    Eptotermin alfa

    go.drugbank.com/drugs/DB11631
    ApprovedWithdrawn

    Eptotermin alfa is an ingredient in the EMA-withdrawn product Osigraft.

    Categories: Drugs for Treatment of Bone Diseases
  7. Drug

    Bepotastine

    go.drugbank.com/drugs/DB04890
    Approved

    Bepotastine was approved in Japan for use in the treatment of allergic rhinitis and uriticaria/puritus in July 2000 and January 2002, respectively, and is marketed by Tanabe Seiyaku Co., Ltd. under the … Bepotastine is a non-sedating, selective antagonist of the histamine 1 (H1) receptor.

  8. Drug

    mRNA-1283

    go.drugbank.com/drugs/DB22668
    ApprovedInvestigational

    previously approved COVID-19 mRNA vaccines, including the original [Moderna COVID-19 Vaccine], mRNA-1283 encodes only the immunodominant regions (NTD and RBD) of the SARS-CoV-2 spike protein, allowing for … [L53413,A274083] mNEXSPIKE was approved by the US FDA in June 2025 for use in patients who have been previously vaccinated with any COVID-19 vaccine and who are at a higher risk of severe outcomes from

  9. Drug

    Betahistine

    go.drugbank.com/drugs/DB06698
    ApprovedInvestigational

    [A220318,L16408] Betahistine is a histamine-like antivertigo drug used for treating symptoms associated with Ménière's disease.

  10. Drug

    Omacetaxine mepesuccinate

    go.drugbank.com/drugs/DB04865
    ApprovedInvestigationalWithdrawn

    Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the plant, Cephalotaxus species. … Then in March 2006, it received Orphan Drug status from the FDA for the treatment of CML.